An OB/GYN at a southeast integrated health network has expertise in menopause, sexual health, general and high-risk obstetrics, and surgery. This stakeholder believes private investment will accelerate innovation in this space, not public NIH funding. Key unmet needs are considered research, prognostics, a gold standard for testing and treatment, and reimbursement. They believe PCOS, pregnancy complications, and perinatal conditions have the highest unmet needs today. The greatest increase in precision medicine activity in the next 1-2 years is expected in pregnancy complications, perinatal conditions, and menopause.This stakeholder is excited by activity from the Jada System, Novocuff, PeriGen, and Astellas (particularly for their menopause drug Fezolinetant). They are also excited for a potential upcoming drug for postpartum depression.

Campaign Details

Precision Medicine Opportunities in Women’s Health Ad Board

DeciBio conducted 11 interviews with OB/GYNs and KOLs in biotech / VC / pharma to explore key unmet needs / challenges, opportunities for precision medicine, and emerging players in women’s health.